A pilot study of pharmacogenomic testing as a tool to enhance depression care in Veterans. | ClinicLens
Modest outcomes from pharmacogenomic (PGx) testing in depression may be influenced by low rates of actionable gene-drug interactions. This 12-week pilot pragmatic randomized clinical trial evaluated the effectiveness of selectively targeting PGx testing to depressed Veterans rece
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.